Pharmacokinetic Studies in Hemodialysis Patients

被引：16

作者：

Atkinson, A. J., Jr. ^{[1
]}

Umans, J. G. ^{[2
,3
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biochem, Chicago, IL 60611 USA

[2] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA

[3] Georgetown Univ, Med Ctr, Dept Obstet & Gynecol, Washington, DC 20007 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 86卷 / 05期

关键词：

INTERCOMPARTMENTAL CLEARANCE; BLOOD FLOW; KINETICS; DRUG; PERMEABILITY; VANCOMYCIN; DIALYSIS; REMOVAL; UREA;

D O I：

10.1038/clpt.2009.147

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intermittent hemodialysis is the primary supportive therapy for patients with end-stage renal disease, who commonly receive several drugs to treat both their underlying disease and the conditions that arise during long-term hemodialysis therapy. Many of these drugs are dialyzable, and their hemodialytic removal may compromise therapeutic efficacy if appropriate supplementary doses are not given. Emergency hemodialysis may also be life-saving for patients who have received drug overdoses or have ingested toxic substances. Optimal therapy in both these clinical settings is critically dependent on the availability of reliable information from well-designed pharmacokinetic studies.

引用

页码：548 / 552

页数：5

共 20 条

[1] Atkinson AJ, 2007, PRINCIPLES OF CLINICAL PHARMACOLOGY, 2ND EDITION, P59, DOI 10.1016/B978-012369417-1/50046-8
[2] ATKISNON AJ, 1977, CLIN PHARMACOL THER, V20, P585
[3] BOWSHER DJ, 1984, J PHARMACOL EXP THER, V230, P269
[4] BOWSHER DJ, 1985, J LAB CLIN MED, V105, P489
[5] GIBSON TP, 1976, CLIN PHARMACOL THER, V20, P720
[6] GIBSON TP, 1985, PHARMACOTHERAPY, V5, P23
[7] HAMPL H, 1978, DIALYSIS TRANSPLANT, V7, P1095
[8] HAMPL H, 1978, DIALYSIS TRANSPLANT, V7, P1179
[9] Evaluation of an in vitro dialysis system to predict drug removal
Hudson, JQ
Comstock, TJ
Feldman, GM
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) : 400 - 405
[10] KOCHWESER J, 1970, ANN NY ACAD SCI, V179, P370

← 1 2 →